Acadia Pharmaceuticals (ACAD) Non-Current Deffered Revenue (2010 - 2012)

Acadia Pharmaceuticals' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $2.4 million for Q2 2012.

• On a quarterly basis, Non-Current Deffered Revenue fell 3.02% year-over-year to $2.4 million in Q2 2012; TTM through Jun 2012 was $2.4 million, a 3.02% decrease from a year earlier, with the FY2011 full-year figure at $2.6 million, down 1.37% from the prior year.
• Non-Current Deffered Revenue fell to $2.4 million in Q2 2012 per ACAD's latest filing, from $2.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $2.6 million in Q4 2010 and bottomed at $2.4 million in Q2 2012.
• The 3-year median for Non-Current Deffered Revenue is $2.5 million (2011), against an average of $2.5 million.
• Across the five-year window, Non-Current Deffered Revenue retreated 1.37% in 2011 and retreated 3.02% in 2012, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $2.6 million in 2010, then dropped by 1.37% to $2.6 million in 2011, then declined by 7.0% to $2.4 million in 2012.
• Per Business Quant, the three latest ACAD Non-Current Deffered Revenue figures stand at $2.4 million (Q2 2012), $2.5 million (Q1 2012), and $2.6 million (Q4 2011).